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Abstract
Background: No single and thoroughly validated imaging method in monitoring of cryoablated
renal cell carcinoma (RCC) is available. The purpose of our study was to determine the feasibility
of dynamic contrast-enhanced perfusion CT (pCT) in evaluating the hemodynamic response of
RCC.
Methods: 15 patients (14 male, 1 female; age range, 43-81 years; mean age, 62 years) with
cryoablated RCC via a transperitoneal approach, underwent to pCT 6-8 months after cryo-
therapy. pCT was performed for 65 seconds after intravenous injection of contrast medium (80
mL, 370 mg iodine per millilitre, 4 mL/sec). Perfusion parameters (Time/Density curve; Blood flow,
BF; Blood Volume, BV; Mean Transit Time, MTT; Permeability-Surface Area Product, PS) were
sampled in the cryoablated tumor area and in ipsilateral renal cortex using deconvolution-based
method. A tumor was considered to be not responsive to treatment by CT evidence of
pathological contrast enhancement in the cryoablated area or renal mass persistence compared
with the preoperative CT control. Written informed consent was obtained from all participants
before the study.
Results: After cryotherapy, successfully ablated tumor (n = 13) showed decrease in BV (5,39 +/-
1,28 mL/100 g), BF (69,92 +/- 20,12 mL/100 g/min) and PS (16,66 +/- 5,67 mL/100 g/min) value and
increased value of MTT (25,35 +/- 4,3 sec) compared with those of normal renal cortex (BV: 117,86
+/- 31,87 mL/100 g/min; BF: 392,39 +/- 117,32 mL/100 g/min; MTT: 18,02 +/- 3,6 sec; PS: 81,68 +/
- 22,75 mL/100 g/min). In one patient, assessment of perfusion parameters was not feasible for
breathing artifacts. One tumor showed poor response to treatment by the evidence of nodular
contrast enhancement in the region encompassing the original lesion. Two typical enhancement
patterns were obtained comparing the Time-Density curves of responsive and not responsive
ablated tumors.
Conclusion: Perfusion CT seems to be a feasible and promising technique in monitoring the
effects of cryoablation therapy.
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Renal cell carcinoma (RCC) is the most common type of
kidney cancer (8.100 deaths and 33.130 expected new
cases in United States for the 2007), encompassed among
highly vascularised tumors [1,2]. Furthermore the com-
mon use of cross-sectional imaging method in clinical
practise has increased the detection of incidental small
RCC [3,4].
Minimally invasive treatments as cryoablation or radioab-
lation have been proposed as a promising alternative to
partial or total nephrectomy in selected cases, especially in
patients who are poor candidates for conventional surgi-
cal resection. Cryoablation of renal tumors can be per-
formed at open, laparoscopic, retroperitoneoscopic
surgery and with imaging guided (Computed Tomogra-
phy, CT; Magnetic Resonance Imaging, MRI) percutane-
ous approaches. By the evidence of effectiveness in renal
tumor constraining of these new thermal therapies, atten-
tion is focused to identify a reliable marker of early resid-
ual tumor and a feasible imaging monitoring protocol.
Vascularity degree of RCC is known as a prognostic factor
correlated with clinical and pathologic stage, metastatic
risk and histopathologic grade and it is a significant pre-
dictor of disease-specific outcome after therapy [5].
Although a standardized and thoroughly validated
method to evaluate tumor vascularity is not available,
some biomarkers have been currently proposed as indexes
of tumor angiogenic activity. In particular, significant
increase of micro vessel density (MVD) and high expres-
sion and secretion of vascular endothelial growth factor
(VEGF), have been reported in tumor tissue [6]. However,
the serial evaluation of these biomarkers as indexes of
tumor activity, needs multiple biopsies and is limited
because of its invasiveness especially during a long-term
follow-up.
An ideal test should be non-invasive, fast, easy to perform,
repeatable and reproducible, and most importantly, it
should provide in vivo early evidence of residual tumor
after therapy and comprehensive data of the tumor struc-
ture with informations on tumor angiogenesis functional
status.
New imaging modalities (MRI, CT) may be used to obtain
informations about microvascular circulation and neoan-
giogenesis. CT is the imaging technique of reference in
surveillance after renal tumor ablation as its ability to dis-
tinguish residual tumor (nodular enhancement within
the ablated lesion) from successfully cryo-ablated lesion
(hypoattenuating areas without focal contrast enhance-
ment with progressive decrease in size).
Therefore, deconvolution-based perfusion computed
tomography (pCT) is a non invasive and fast new CT tech-
nology that allows measurement of tumor vascular physi-
ology analyzing the time course of tissue enhancement
using sequential CT acquisitions during bolus injection of
a contrast medium.
This technique generates functional maps and represents
in a color scale pixel values the following perfusion
parameters: blood flow (BF), blood volume (BV), mean
transit time (MTT) and vascular permeability- surface area
product (PS). This type of study can also be repeated at
different time periods to assess tumor response to thermal
therapy to detect temporal changes in tumor angiogen-
esis.
In our study, we aimed to examine the feasibility of
deconvolution-based pCT in monitoring cryoablated RCC
and to evaluate whether perfusional CT parameters corre-
late with response to therapy.
Methods
Population
Between May 2007 and June 2008, 15 patients (14 male,
1 female; mean age, 62 years; age range, 43-81 years),
underwent to laparoscopic cryoablation for renal tumors
(12 renal cell carcinoma, 3 angiomyolipoma), were
enrolled in pCT monitoring protocol. In each patient the
tumor mean size was 2,04 cm (range 1,5-2,9 cm), show-
ing heterogeneous contrast enhancement in pre-treatment
contrast enhanced CT or MRI, not extended beyond
Gerota fascia and with no evidence of distant metastases.
The meantime interval between cryoablation procedure
and post-therapeutic pCT was 6-8 months. Pre-treatment
enhanced CT or MRI images were used as a reference for
identification of primitive lesion. Additionally, approxi-
mately 6 months postoperatively, CT directed core needle
biopsies of the cryoablated tumor were obtained for his-
tophathological examination. All patients were informed
of the investigational nature of the study and signed a
written consent for participation in accordance with insti-
tutional guidelines.
Cryoablation Procedure
All the patients underwent to laparoscopic cryoablation of
the renal lesion via a transperitoneal approach. Briefly,
our technique include: an open access through the
umbilicus, kidney mobilization, visualization of the
entire exophytic aspect of the tumor surface, excision of
the overlying fat for pathological examination, imaging of
the tumor and entire kidney with a steerable laparoscopic
ultrasound (US) probe, guided core needle biopsy of the
tumor and, finally, puncture renal cryoablation under
laparoscopic and real-time intracorporeal sonographicPage 2 of 11
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engulf completely the renal tumor in the iceball further
extending the iceball margins approximately 1 cm beyond
the tumor edge [7].
Intraoperative pre-cryoablation needle biopsy confirmed
renal cell carcinoma (RCC) in 11 patients (73%) and mis-
cellaneous conditions in the remaining 4 patients (27%),
including normal kidney tissue in 1, fibrous tissue in 1,
angiomyolipoma in 1, oncocytoma in 1.
Perfusion CT (pCT) technique
Perfusion study was performed with a 64 multi-detector
row CT scanner (LightSpeed VCT; GE Medical Systems,
Milwaukee, USA). Unenhanced low-dose CT of the upper
abdomen (120 kVp, 180 mA, slice thickness 5 mm, 0,6-
second gantry rotation time, acquisition mode 27.50/
1.375:1, large FOV, matrix 512 × 512) was performed in
quite respiration to localize the side of cryoablated tumor.
The images were then analyzed by an expert radiologist
(ES) experienced in renal tumours, with scans planned to
a 40-mm acquisition range for pCT to include the maxi-
mum cryoablated area visible. A single radiologist (GM)
with a 5 years practice in perfusion CT supervised the
acquisition of all the perfusion studies.
The anatomical coverage of pCT is limited on the z-axis, as
the acquisition is performed in static table position with a
scan range of 40 mm. pCT was performed with cine tech-
nique with a delay time of 7 sec after the injection of 80
mL non-ionic iodinated contrast material (iopromide,
Ultravist 370; Bayer-Schering), followed by 40 mL of
saline solution, injected at a rate of 4 mL/sec by an 18-20
Gauge cannula in the antecubital vein with automatic
injector (Stellant, Medrad, Pittsburg, Pa). First-pass scan
was obtained with a sampling rate of 1 acquisition per sec-
ond with a time duration of 45 seconds. After a 25 sec-
onds, a delayed-phase was acquired at the same level with
a time duration of 20 seconds. The CT was acquired dur-
ing quiet respiration and continued for a total time of 65
seconds.
The following parameters were used for dynamic study:
eight contiguous 5 mm sections at the same table posi-
tion, 1-second gantry rotation time, 120 kVp, 80 mA, and
65-seconds acquisition time. The images were recon-
structed at a 5 mm thickness and 0,5 sec intervals. The
mean effective dose for each patient was about 13 mSv.
Image Analysis
Data acquired during cine scan were transferred onto an
image processing workstation (Advantage Windows 4.4;
GE Medical Systems) provided with commercially availa-
ble software for functional analysis with deconvolution-
based technique (Perfusion 3; GE Medical Systems).
The software, after the selection of a threshold value to
exclude bone density from the measurements, required to
manually or automatically identify arterial input function
(AIF) of contrast medium concentration by a 10 mm2 (18-
20 pixel area) region of interest (ROI) manually drawn in
the abdominal aorta which was always enclosed in the
field of view. Selecting a perpendicular-to-section running
artery, it was possible to avoid partial volume artifacts that
may underestimate reference blood density, leading to
misreporting tissue perfusion data.
Then, the software generates Time/Density (Second/
Hounsfield Unit) curves from standardized circular
regions of interest (ROIs; 10 mm2; 18-20 pixel range)
manually positioned in the cryoablated area. Care was
taken to embed as much of the solid portions of the tumor
as possible in order to exclude the necrotic regions and to
avoid tumor limits exceeding to exclude peritumoral
hyperaemia. Similar circular ROI was placed in healthy
omolateral parenchyma as a control to assess perfusion
differences between tumor lesion and normal paren-
chyma.
The graphic representation of contrast perfusion during
and immediately after the administration of contrast
material was used to obtain the following quantitative
parameters of contrast enhancement kinetic:
- Time of arrival (TA), the time between the beginning
of dynamic acquisition and onset of enhancement
- Time to peak (TTP), time between onset of enhance-
ment and maximum enhancement
- Peak contrast enhancement (PCE), maximum den-
sity value
- Wash-in-rate (WIR), peak value after tissue enhance-
ment - CT value of baseline/time period reaching the
tissue peak value from baseline.
Therefore, the software provided in a colour scale pixel,
maps of functional parameters for blood flow (BF), blood
volume (BV), and mean transit time (MTT) using the cen-
tral volume principle [8,9]. The capillary permeability-
surface area product (PS) was calculated according to the
following equation: PS = - blood flow [ln (1- E)], where E
is the extraction fraction (the fraction of contrast material
that leaks into the extravascular space from the intravascu-
lar space) [10].
Contrast-enhanced images were superimposed on the col-
our map in order to facilitate visual identification of the
cryoablated area. BF (in millilitres per 100 g of wet tissue
per minute) is defined as the flow rate of blood throughPage 3 of 11
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:138 http://www.jeccr.com/content/28/1/138the vascular net in a tissue. BV (in millilitres per 100 g of
wet tissue) is the volume of blood within the vascular net
of a tissue that was flowing and not stagnant. Mean transit
time (in seconds) corresponds to the average time taken
by the blood elements to traverse the vasculature from the
arterial end to the venous end. PS (in millilitres per 100 g
of wet tissue per minute) is the product of permeability
and the total surface area of capillary endothelium in a
unit mass of tissue representing the total diffusion flux
across all capillaries.
The pCT is based on a tracer kinetic analysis in which
enhancement of the tissue (HU), sampled during arrival
of the contrast agent by cine CT scanning, is linearly pro-
portional to the concentration of contrast agent in the tis-
sue. Thus, the time-attenuation curves for the regions of
interest were analyzed by means of a mathematical decon-
volution method that takes advantage from this linear
relationship between the iodine concentration and the CT
attenuation numbers.
In particular, deconvolution method uses arterial input
function (AIF) to which compare the curve obtained on
parenchimal ROIs so as to correct the effect of bolus dis-
persion and better reflect the tracer kinetic model, which
requires an instantaneous bolus input and tissue time-
attenuation curves to calculate the impulse residue func-
tion (IRF) which is the time enhancement curve of the tis-
sue due to an idealized instantaneous injection of one
unit of tracer. It is characterized by an instantaneous peak
to a plateau, as the contrast material enters and remains
within the tissue, followed by decays as the contrast mate-
rial washes out from the tissue. The height of the function
gives the tissue blood flow (BF) and the area under the
curve determines the relative blood volume (BV) [11-13].
Deconvolution analysis is most widely used in acute cere-
brovascular disease in which the blood brain barrier is
intact. However, in oncologic disease the neo-angiogen-
esis induces the formation of immature and leaky vessels,
which results in heterogeneous microcirculation with
interstitial diffusion of tracer (contrast agent). This
requires a correction method, as proposed by Nabavi et al
[14], in assessing PS parameter according to the Renkin-
Crone equation, E = 1 - exp (-PS/BF), to avoid inaccurate
determination of blood flow when compartment model is
used.
According to a previous study [15], tumor was considered
successfully ablated by no evidence of enhanced focal
masses within the treated lesion that frequently decreases
in size. Perfusion parameters were obtained in tumor cry-
oablated area and in normal ipsilateral renal cortex to ver-
ify the changes in perfusion parameters due to cryo-
therapy. No post-procedural biopsy was performed on
any tumor. Hence a small number of patients were
enclosed in our preliminary study, no statistical analysis
was performed.
Results
Good image quality was obtained in 14 of 15 patients. 1
Patient had technically inadequate pCT examination due
to motion artifacts with data not included in the analysis.
1 patient showed residual tumour. The perfusion parame-
ters (TA, TTP, wash-in rate, Peak contrast enhancement
and BV, BF, PS and MTT) in the cryoablated area and nor-
mal renal parenchyma of 14 patients were calculated and
comparatively evaluated (Table 1, 2). Two pattern curves
with different morphology were generated analyzing
Time/Density plots. A particular pattern (Type 1), charac-
terised by rapid density increase and tendency to decrease
after density peak, was observed in the patient (n = 1) with
evidence of residual tumor (Figure 1). A second character-
istic curve (Type 2), with steady density increase or a pla-
teau following an initial rise, was identified in patients (n
= 13) responsive to treatment, with no evidence of resid-
ual tumor (Figure 2).
Ablation responders (n = 13) showed a peak contrast
enhancement (PCE; HU) in cryoablated area after
medium contrast administration with a mean-value of
60,91 ± 14,85 [vs. 281,77 ± 37,6 in ipsilateral normal
renal cortex]. In the same group the evaluation of kinetic
parameters [vs. ipsilateral renal cortex] showed a time of
arrival (TA; sec) of 15,96 ± 1,2 [14,85 ± 0,65], a time to
peak (TTP; sec) of 59,13 ± 2,87 [49,4 ± 4,4], a wash-in-rate
(WIR; 1/s) of 0,66 ± 0,41 [7,04 ± 1,35] (Table 1). Further-
more in the same cases, a variable trend of reduction in
BF, BV, and PS values and increase in MTT values were
observed in tumor ablated area compared to normal renal
cortex (Table 2). In particular the BV, BF and PS mean val-
ues sampled in the cryoablated area were lower than in
normal renal cortex (respectively: 5,39 ± 1,28 mL/100 g vs
117,86 ± 12,53 mL/100 g; 69,92 ± 20,12 mL/100 g/min
vs 392,28 ± 117,32 mL/100 g/min; 16,66 ± 5,67 mL/100
g/min vs 81,68 ± 22,75 mL/100 g/min). MTT was higher
in cryoablated area than normal parenchyma (25,35 ± 4,3
sec vs 18,02 ± 3,6 sec).
On the contrary 1 patient had local residual tumor evi-
denced by renal mass persistence and pathological con-
trast enhancement with nodular feature in the cryoablated
area (TA 14,3 sec; TTP 38,3 sec; WIR 11,56/sec; PCE
301,23 HU) compared to normal ipsilateral cortex (TA
13,8 sec; TTP 44,4 sec; WIR 9,41; PCE 374,18 HU). The
mean BV value at the same residual tumour area was
140,68 ± 24,48 mL/100 g (vs. BV of 116,14 ± 14,27 in
normal parenchyma), BF and PS mean values respectively
were 562,72 ± 97,96 mL/100 g/min (vs. 393,8 ± 59,01
mL/100 g/min in normal parenchyma) and 73,52 ± 28,1Page 4 of 11
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Cryoablated Renal Cell Carcinoma (RCC) in the right kidney of a 47 years-old patientFigure 1
Cryoablated Renal Cell Carcinoma (RCC) in the right kidney of a 47 years-old patient. a) Perfusional CT scan 
shows three regions of interest, selected on abdominal aorta (ROI 1), normal ipsilateral renal cortex (ROI 2), cryoablated 
tumor area (ROI 3). b) The corresponding time-density curves show contrast enhancement kinetic with typical pattern at 
responsive cryoablated tumor area (curve 3: slower initial enhancement, decreased amplitude, slower wash-out) compared to 
abdominal aorta (curve 1) and ipsilateral normal renal cortex (curve 2). Blood colour maps (c, Blood Volume, BV; d, Blood 
Flow, BF; e, Permeability - Surface Area Product, PS) at the same levels, show the high arterial (ROI 1) and parenchymal (ROI 
2) perfusion parameters with no colour encoding in successfully cryoablated area (ROI 3).
Journal of Experimental & Clinical Cancer Research 2009, 28:138 http://www.jeccr.com/content/28/1/138
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Residual renal cancer cell (RCC) in right kidney, six months after cryoablationFigure 2
Residual renal cancer cell (RCC) in right kidney, six months after cryoablation. Pre-treatment contrast-enhanced 
cortico-medullary phase CT scan (a) shows exophytic solid tumor with heterogeneous contrast-enhancement. Post-treatment 
perfusional CT (b) shows a nodular enhancing component (ROI 3) in the medial portion of the ablation zone with peripheral 
linear enhancement in the peri-renal fat, suggestive for residual tumour. Regions of interest were placed in abdominal aorta 
(ROI 1), normal renal cortex (ROI 2) and nodular solid enhancement area (ROI 3) to measure perfusional parameters. Time/
Density curve (c) shows a typical contrast enhancement pattern in residual tumour area with fast and early wash-in, a plateau 
trend and a slow, progressive and uniform wash-out (curve 3). Color maps superimposed on gray-scale images (d, Blood Vol-
ume, BV; e, Blood Flow, BF) of right kidney show high colour encoding in corresponding residual tumour area: (d) BV (mean, 
140,68 ± 24,48 mL/100 g wet tissue/min), (e) BF (mean, 562,72 ± 97,96 mL/100 g wet tissue).
Journal of Experimental & Clinical Cancer Research 2009, 28:138 http://www.jeccr.com/content/28/1/138mL/100 g/min (vs. 41,88 ± 19,89 mL/100 g/min in nor-
mal parenchyma). MTT was 15 ± 0,1 sec (vs. 17,69 ± 0,4
sec in normal parenchyma).
At a six months postoperative follow-up, 11 patients
(73%) underwent CT guided percutaneous core needle
biopsy. Two/Three needle cores were obtained per patient
with a spring loaded, 18 gauge core biopsy device. Accord-
ing to pCT results with one case of persistent disease, of 25
needle cores obtained, two specimen of RCC were identi-
fied in 1 patients. This patient was scheduled for salvage
laparoscopic cryoablation and is currently under image
monitoring without actual evidence of local residual or
metastatic disease at the 12 months follow-up. In the
remaining 23 needle cores available, a varying evidence of
irreversible cell death was depicted including: hemosi-
derin deposits in 10 (43%), coagulative necrosis in 8
(35%), and fibrosis in 5 (22%) cores.





Time of arrival, TA (s)
14,3 15,96 ± 1,29
[13,8] [14,85 ± 0,65]
Time to peak, TTP (s)
38,3 59,13 ± 2,87
[39]
Wash-in rate (1/s)
11,52 0,66 ± 0,41
[9,41] [7,04 ± 1,35]
Peak contrast enhancement (HU)
300,3 60,91 ± 14,85
[374,18] [281,77 ± 37,6]
*Values are expressed as mean ± standard deviation (SD).







(BV; mL/100 g wet tissue)
140,68 ± 24,48 5,39 ± 1,28
[116,14 ± 14,27] [117,86 ± 12,53]
Blood Flow
(BF; mL/100 g wet tissue/min)
562,72 ± 97,96 69,92 ± 20,12
[393,8 ± 59,01] [392,28 ± 117,32]
Permeability- Surface Area Product
(PS; mL/100 g wet tissue/min)
73,52 ± 28,1 16,66 ± 5,67
[41,88 ± 19,89] [81,68 ± 22,75]
Mean Transit Time (MTT; sec)
15 ± 0,1 25,35 ± 4,3
[17,69 ± 0,4] [18,02 ± 3,6]
*Values are expressed as mean ± standard deviation (SD).Page 7 of 11
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Perfusion imaging is a non-invasive functional technique
firstly introduced by Miles [16,17] and implemented for
the evaluation of neoplastic disease on account of its diag-
nostic and prognostic value as observed for treatment
response of lymphoma [18] and head-and-neck cancer
[19], for predictive malignancy value in pulmonary soli-
tary nodule [20], for monitoring of hemodynamic
changes after anti-angiogenic therapy [21]. The growing
availability of new multislice computed tomographies
(MSCTs) and software programs for post-processing per-
fusion measurements have allowed additional functional
informations regarding flow quantification of cross sec-
tion areas. As far as we know, there are no published
reports about the use of pCT in monitoring of cryoablated
RCC.
Cryoablation technique is a thermal minimally invasive
treatment, developed as an alternative to conventional
surgical resection in patients with selected case of RCC,
especially for whom the risk of surgery is too great [9,22-
28].
The area of necrosis resulting from cryoablation is
directed by cytotoxic effect from intracellular ice crystalli-
zation during the active freezing cycles and micro-occlu-
sive tissue ischemia by the active or passive thaw cycle
[29]. With time fibrosis occurs and the ablated area
decreases in size. Although cryoablation of select renal
masses is an effective technique in local tumor control
[28,30], the ablated renal tumor area is not excised.
Indeed accurate monitoring of the ablation zone and early
post-ablative detection of residual or recurrent tumor has
a pivotal importance.
CT is a widespread technique in cryoablated renal tumors
monitoring allowing morphologic imaging of the kidney
during several enhancement phases, in a tri-phases acqui-
sition. The multiphasic acquisition with the new MSCTs
provides a representation of each component of contrast
enhancement (intravascular and extravascular). There-
fore, the use of functional imaging techniques to assess
tissue perfusion and permeability allows a more deeply
angiogenesis process analysis of the tumor with func-
tional informations that cannot be appreciated from qual-
itative or quantitative (UH) analysis of static tri-phase
contrast enhanced images. Furthermore it implies a mar-
gining of factors other than angiogenesis that may influ-
ence the quantification of contrast enhancement (e.g.
amount of contrast agent, patient weight, cardiac output)
[31].
The advent of multislice CT scanner with new perfusion
software programs creates a unique opportunity for imag-
ing as a reproducible method to assess, in vivo and more
deeply than the qualitative evaluation of contrast
enhancement, tumor vascularity for monitoring and pos-
sibly predicting clinical response to cryotherapy. Other-
wise, the common imaging criteria of lesion shrinkage to
assess tumor response to cryotherapy may not be the ideal
technique of detecting in vivo activity and clinical out-
come of ablation and may be implemented with func-
tional imaging parameters from tumor ablated area to
obtain much reliable post-treatment informations.
RCC is a highly vascularised tumor with verified correla-
tion between contrast enhancement measures and micro-
vessel density [32] and between its quantification and
prognostic information in early-stage of RCC [15,19].
It is well known that neoangiogenesis is a crucial factor for
tumor cell growth and metastatic potential in cancer dis-
ease, inversely related with patient survival [33]. This
process is characterized by increased microvessel density
and microanatomical changes of new vessels related to
fenestration of the basement membrane resulting in
anomalous tissue perfusion compared to normal paren-
chyma and an increase in the permeability to large mole-
cules in blood.
Considering that tumor neoangiogenesis induces patho-
physiological abnormalities to the hemodynamic envi-
ronment surrounding the tumor, anomalous tissue
perfusion can be qualitatively and quantitative expressed
in time-enhancement curves and in colour map measure-
ments in a perfusional contrast-enhanced study [31,34].
The degree of contrast enhancement closely matches with
the physiological changes of tumor angiogenesis process
such as microvessel density, intratumoral/intravascular
volume fraction, the tumor blood flow, the vascular per-
meability-surface area product and the accessible extravas-
cular-extracellular space, all of which result in increased
contrast enhancement related to the intensity of neovas-
cularisation [11,31].
Tumor response to non surgical therapies is closely related
to tissue perfusion and local oxygen delivery after treat-
ment, attributed in large part to neoangiogenesis [19,35].
On the contrary, cryoablation destroys tissue, indirectly
erasing tumor perfusion by means of microvascular dam-
age-induced ischemia, but to date this has not been dem-
onstrated using pCT. Although actually no single test has
been validated for neoangiogenesis measurements, in a
previous study perfusion-CT positively related with tumor
MVD in neo-vascularised areas of RCC [36].
In the tumor response assessment, common imaging fea-
tures, used to define successfully cryoablated tumors,Page 8 of 11
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:138 http://www.jeccr.com/content/28/1/138relies on shrinkage and no focal contrast enhancement in
the treated area at morphology evaluation [15,30,37].
Therefore, some Authors reported a threshold of enhance-
ment (10 HU) to distinguish suspected residual tumor
(>10 HU) from successfully ablated zone (<10 HU),
mostly after radio-frequency ablation rather than cryoab-
lation [38-41]. This quantitative parameter of favourable
imaging outcome has not been confirmed by pathology
and only a few studies investigated cryoablated areas spec-
imens during follow-up. Weight J.C. et al [42], provide the
largest available series regarding the correlation between
imaging findings and pathology results after renal tumors
cryoablation with favourable agreement between imaging
and pathological essays at a 6-months follow-up. Using
the morphologic criterion of central nodular enhance-
ment as a predictive feature of positive biopsy in their
series, the sensitivity was 77.8% with a 95.1% specificity,
63.4% PPV and 97.7% NPV.
We found two different trend in Time/Density curves of
successfully cryoablated area and residual tumour lesion
that may be a practical approach during imaging follow-
up in early detection of not responsive disease. Overall, in
successfully cryoablated area we identified a typical pat-
tern of contrast-enhancement without arterial wash-in
and slow wash-in with a plateau trend. Although just
observed in one patient, the contrast enhancement curve
of the residual tumour area is defined by a fast and early
wash-in, a plateau trend and a slow, progressive and uni-
form wash-out. In line with these findings, our study also
provided a positive correlation between kinetics parame-
ters measured Time/Density curves and quantitative
measurement of contrast enhancement (BV, BF, MTT, PS).
Successfully cryoablated area demonstrated decreased
value of BV, BF and PS and increased value of MTT com-
pared to the normal renal parenchyma.
These two patterns can be useful to distinguish residual
tumor from successfully treated area, which enhances and
washes-out slowly. Thus, viable tumors tend to have high
contrast-enhancement reflected as in colour scale on par-
ametric images, whereas area responsive to treatment
show no change in colour. In our experience, the use of
pCT as a sensitive technique in the in-vivo detection of
tumor angiogenesis can improve the identification of
residual tumor after therapy from normal tissues or from
peri-tumoral area on the basis that angiogenesis, and its
physiological imaging findings, can be used as a marker of
viable tumor.
Limitations of this study included the availability of
matching post-cryoablation imaging results and patho-
logical specimens. We know that core kidney biopsies
have a non-diagnostic rate of 20% [43] and a 20% false-
negative rate [44] with Weight J.C. reporting an high pre-
dictive value of treatment outcome using only imaging
findings [42].
In our study, we observed some non-homogeneous densi-
ties (inter- or intralesional) of the treated area, resulting in
a wide standard deviations of the perfusion parameters.
This heterogeneity could be a pitfall related to perfusion
values measures of ROIs (variable in size and location)
placed on the cryoablated area. We tried to limit the
impact of this heterogeneity by sampling the functional
parameters using standard sized ROIs drawn at the same
level, including only solid area and by excluding necrotic
regions.
In our experience pCT provides direct and early evidence
of a therapeutic effect by demonstrating changes in the
enhancement curves with a slower initial enhancement,
decreased amplitude, slower wash-out (Figure 1). In one
case, cryotherapy failure in some tumor areas, may be
related to the presence of resistant disease subsequently
early detected and submitted to additional treatment for
control. Furthermore, as a high sensitivity and high specif-
icity method in evaluation of tumor vascularity [11], pCT
may be implemented in pre-treatment imaging protocol
for clear identification of patients taking an advantage
from antiangiogenic therapy [36]. Otherwise, considering
the strong colour encoding of the renal parenchyma due
to the kidney's high perfusion rate, the implementation of
pre-treatment pCT in common imaging protocols may be
a useful tool of tumoral vascular structure characterization
aimed to tumor area post-treatment follow-up monitor-
ing.
Conclusion
pCT can detect minimal focal perfusion changes whether
the tumor is shrinking or without tumor volume changes,
possibly indicating, as in vivo marker of neoangiogenesis,
early reversal of tumor responsiveness to cryotherapy by
distinguishing cryoablated areas from normal renal adja-
cent parenchyma.
New imaging CT scanners coming with user-friendly post-
processing software will perform integrated and reproduc-
ible measurements based not only on tumor morphology
but also on tumor function. In particular, the quantitative
assessment of perfusional measurements, superimposed
to the common used size-based criteria may improve
tumor detection and evaluation of therapeutic response.
Optimized protocols need to be defined for reducing
motion-related artifacts with the minimum-required dose
for fairly perfusion measurements. In this study, the
promising role of pCT as predictive method for early
detection of residual tumor is considered to be prelimi-Page 9 of 11
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:138 http://www.jeccr.com/content/28/1/138nary because of the small number of patients. Therefore,
additional studies with larger numbers of patients are aus-
picable to verify these promising results.
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